Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2005

View Archived Issues

Clearance for phase I study of 1D09C3 in Germany

PainCeptor selects preclinical development lead candidates for key programs

Edison receives FARA grant to develop EPI-A0001 for Friedreich's ataxia

CTCE-9908 prevents human prostate cancer metastases in preclinical study

New phase I study for Heplisav HBV vaccine

Epitan reports results from European PMLE phase II study of EPT-1647

Weight loss seen in phase I study of oleoyl-estrone

Nicholas Piramal to acquire Avecia Pharmaceuticals

InterMune enrolls 600th patient in pivotal INSPIRE study

Approval for phase I study in Stem Cell Therapeutics' stroke program

European phase II trial studies Uvidem for melanoma

Aphton and sanofi pasteur to terminate Insegia agreements

European approval for Zeldox for manic or mixed episodes in bipolar disorder

Recent Ligand patent discloses novel androgen receptor modulators

Recent patents cover novel treatments for neurological disorders

Boehringer Ingelheim patents novel agents for treating inflammation

AVE-8062 reported to prevent proliferation of solid tumors in rats

KLF5 antagonists may play a role in the treatment of vascular diseases

SELENBP1 identified as candidate gene for schizophrenia using novel approach

New broad-spectrum antibiotics with a novel mechanism of action

Lentivirus-mediated gene therapy for sickle cell anemia and thalassemia to soon enter clinical trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...